H3N2 Infection - Pipeline Review, H1 2016

H3N2 Infection - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2016’, provides an overview of the H3N2 Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H3N2 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H3N2 Infection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
The report reviews pipeline therapeutics for H3N2 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved H3N2 Infection therapeutics and enlists all their major and minor projects
The report assesses H3N2 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for H3N2 Infection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
H3N2 Infection Overview
Therapeutics Development
Pipeline Products for H3N2 Infection - Overview
Pipeline Products for H3N2 Infection - Comparative Analysis
H3N2 Infection - Therapeutics under Development by Companies
H3N2 Infection - Therapeutics under Investigation by Universities/Institutes
H3N2 Infection - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
H3N2 Infection - Products under Development by Companies
H3N2 Infection - Products under Investigation by Universities/Institutes
H3N2 Infection - Companies Involved in Therapeutics Development
AIMM Therapeutics B.V.
Aphios Corporation
Crucell N.V.
CSL Limited
Glide Pharmaceutical Technologies Limited
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
NanoViricides, Inc.
Novavax, Inc.
OPKO Health, Inc.
Sarepta Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
Visterra, Inc.
Zydus Cadila Healthcare Limited
H3N2 Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
APP-0205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-8020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-9114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FluGEM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gamma-Flu - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H3N2] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H3N2] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-872 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PNSIA-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radavirsen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for RSV and Influenza A Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXB-248 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VIS-410 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
H3N2 Infection - Recent Pipeline Updates
H3N2 Infection - Dormant Projects
H3N2 Infection - Product Development Milestones
Featured News & Press Releases
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for H3N2 Infection, H1 2016
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2016
H3N2 Infection - Pipeline by AIMM Therapeutics B.V., H1 2016
H3N2 Infection - Pipeline by Aphios Corporation, H1 2016
H3N2 Infection - Pipeline by Crucell N.V., H1 2016
H3N2 Infection - Pipeline by CSL Limited, H1 2016
H3N2 Infection - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016
H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016
H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
H3N2 Infection - Pipeline by Johnson & Johnson, H1 2016
H3N2 Infection - Pipeline by Medicago Inc., H1 2016
H3N2 Infection - Pipeline by MedImmune, LLC, H1 2016
H3N2 Infection - Pipeline by Mucosis B.V., H1 2016
H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2016
H3N2 Infection - Pipeline by Novavax, Inc., H1 2016
H3N2 Infection - Pipeline by OPKO Health, Inc., H1 2016
H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016
H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
H3N2 Infection - Pipeline by Visterra, Inc., H1 2016
H3N2 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2016
H3N2 Infection - Dormant Projects, H1 2016
List of Figures
Number of Products under Development for H3N2 Infection, H1 2016
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook